Frosch, Z., Masaquel, A., Fox, D., Reyes, C., Cassoli, L., Lai, D., Myers, K., Bussberg, C., Patel, K. (2025). Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs). Blood. https://doi.org/10.1182/blood-2025-6179